Groupe Hospitalier du Havre Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2018
NCT03626519
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Groupe Hospitalier du Havre

Active Ingredients

Drugs in Phase 3 Trials (1)

ropivacaine (naropin) (1 trial)

Drugs in Other Trials (1)

menthol (Salonpas) (1 trial)

Indications

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2